2. Search Result
Search Result
Results for "

PDE1-IN-2

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

3

Isotope-Labeled Compounds

Cat. No. Nombre del producto Target Áreas de investigación Chemical Structure
  • HY-15455
    Roflumilast
    Maximum Cited Publications
    14 Publications Verification

    APTA-2217; BYK 20869; B9302-107

    		 Phosphodiesterase (PDE) RSV Inflammation/Immunology
    Roflumilast (APTA-2217) is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDE4A4, PDE4B1, and PDE4B2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells.
    Roflumilast
  • HY-14254A
    Olprinone
    1 Publications Verification

    LoprINone

    		 Phosphodiesterase (PDE) Cardiovascular Disease
    Olprinone (Loprinone) is a potent phosphodiesterase (PDE) 3 inhibitor, with IC50s of 150, 100, 0.35 and 14 μM for PDE1, PDE2, PDE3 and PDE4, respectively. Olprinone is used for the research of heart failure due to its positive inotropic and vasodilative effects. Anti-inflammatory activity .
    Olprinone
  • HY-10790
    Cilomilast
    3 Publications Verification

    SB-207499

    		 Phosphodiesterase (PDE) Inflammation/Immunology
    Cilomilast (SB-207499) is a potent, selective and orally active inhibitor of Phosphodiesterase 4 (PDE4), with IC50s of ~100 and 120 nM for LPDE4 and HPDE4, respectively. Cilomilast shows selectivity for PDE4 over PDE1, PDE2, PDE3 and PDE5 (IC50=74, 65, >100, and 83 μM, respectively). Cilomilast has anti-inflammatory and immunomodulatory effects and can be used for thr research of asthma and chronic obstructive pulmonary disease (COPD) .
    Cilomilast
  • HY-101490
    PDE1-IN-2

    		Phosphodiesterase (PDE) Neurological Disease
    PDE1-IN-2 is a PDE1 inhibitor extracted from patent WO2016/55618 A1, example 31. PDE1-IN-2 has IC50 values of 6 nM, 140 nM and 164 nM for PDE1C, PDE1B and PDE1A, respectvely. PDE1-IN-2 is developed for the research of neurodegenerative disorders and psychiatric disorders .
    PDE1-IN-2
  • HY-14254
    Olprinone Hydrochloride
    1 Publications Verification

    LoprINone Hydrochloride

    		 Phosphodiesterase (PDE) Cardiovascular Disease
    Olprinone (Loprinone) Hydrochloride is a potent phosphodiesterase (PDE) 3 inhibitor, with IC50s of 150, 100, 0.35 and 14 μM for PDE1, PDE2, PDE3 and PDE4, respectively. Olprinone Hydrochloride is used for the research of heart failure due to its positive inotropic and vasodilative effects. Anti-inflammatory activity .
    Olprinone Hydrochloride
  • HY-15455S
    Roflumilast-d4
    1 Publications Verification

    APTA-2217-d4; BYK 20869-d4; B9302-107-d4

    		 Isotope-Labeled Compounds Phosphodiesterase (PDE) RSV Inflammation/Immunology
    Roflumilast-d4 is the deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells .
    Roflumilast-d4
  • HY-156434
    PDE11A4-IN-1

    		Phosphodiesterase (PDE) Neurological Disease
    PDE11A4-IN-1 (compound 23b) is a potent and selective PDE11A4 inhibitor with an IC50 of 12 nM. PDE11A4-IN-1 show high selectivity for PDE11A4 over PDE1, PDE2, PDE7, PDE8, and PDE9 .
    PDE11A4-IN-1
  • HY-15455R
    Roflumilast (Standard)

    APTA-2217 (Standard); BYK 20869 (Standard); B9302-107 (Standard)

    		 Reference Standards Phosphodiesterase (PDE) RSV Inflammation/Immunology
    Roflumilast (Standard) is the analytical standard of Roflumilast. This product is intended for research and analytical applications. Roflumilast (APTA-2217) is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells.
    Roflumilast (Standard)
  • HY-112631
    OPC 33540

    		Phosphodiesterase (PDE) Cardiovascular Disease
    OPC-33540 is a highly selective and competitive PDE3 inhibitor with IC50 values of 0.32 nM (PDE3A) and 1.5 nM (PDE3B). OPC-33540 exhibits IC50s against PDE1, PDE2, PDE4, PDE5, and PDE7 of 42.9, 52.3, 100.8, 2.5, and 51.3 μM, respectively. OPC-33540 significantly enhances cAMP accumulation in platelets and effectively inhibits thrombin-induced platelet aggregation. OPC-33540 can be used in antithrombotic studies .
    OPC 33540
  • HY-15455S2
    Roflumilast-d3

    APTA-2217-d3; BYK 20869-d3; B9302-107-d3

    		 Isotope-Labeled Compounds Phosphodiesterase (PDE) RSV Inflammation/Immunology
    Roflumilast-d3 is deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells.
    Roflumilast-d3
  • HY-15455S1
    Roflumilast-d4 N-Oxide

    		Phosphodiesterase (PDE) RSV Inflammation/Immunology
    Roflumilast-d4 N-Oxide is the deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells .
    Roflumilast-d4 N-Oxide
  • HY-14254AR
    Olprinone (Standard)

    LoprINone (Standard)

    		 Phosphodiesterase (PDE) Reference Standards Cardiovascular Disease
    Olprinone (Standard) is the analytical standard of Olprinone. This product is intended for research and analytical applications. Olprinone (Loprinone) is a potent phosphodiesterase (PDE) 3 inhibitor, with IC50s of 150, 100, 0.35 and 14 μM for PDE1, PDE2, PDE3 and PDE4, respectively. Olprinone is used for the research of heart failure due to its positive inotropic and vasodilative effects. Anti-inflammatory activity .
    Olprinone (Standard)
  • HY-170435
    PDE5-IN-13

    		Phosphodiesterase (PDE) Cardiovascular Disease
    PDE5-IN-13 (Compound 14b) inhibits phosphodiesterase 5 (PDE5A) with an IC50 of 3 nM. PDE5-IN-13 is a potential candidate for PAH (pulmonary arterial hypertension) research. PDE5-IN-13 has high selectivity for targets over PDE1, PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11. PDE5-IN-13 is orally active .
    PDE5-IN-13
  • HY-105349
    T-0156

    		Phosphodiesterase (PDE) Neurological Disease
    T-0156 is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. T-0156 specifically inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by PDE5 in a competitive manner (IC50=0.23 nM). T-0156 inhibits PDE6 (IC50=56 nM) and has low potencies against PDE1, PDE2, PDE3, and PDE4 (IC50>10 μM). T-0156 enhances the nitric oxide (NO)/cGMP pathway .
    T-0156
  • HY-10790R
    Cilomilast (Standard)

    SB-207499 (Standard)

    		 Phosphodiesterase (PDE) Reference Standards Inflammation/Immunology
    Cilomilast (Standard) is the analytical standard of Cilomilast. This product is intended for research and analytical applications. Cilomilast (SB-207499) is a potent, selective and orally active inhibitor of Phosphodiesterase 4 (PDE4), with IC50s of ~100 and 120 nM for LPDE4 and HPDE4, respectively. Cilomilast shows selectivity for PDE4 over PDE1, PDE2, PDE3 and PDE5 (IC50=74, 65, >100, and 83 μM, respectively). Cilomilast has anti-inflammatory and immunomodulatory effects and can be used for thr research of asthma and chronic obstructive pulmonary disease (COPD) .
    Cilomilast (Standard)
  • HY-164685
    T-0156 free base

    		Phosphodiesterase (PDE) Neurological Disease
    T-0156 free base is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. T-0156 free base specifically inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by PDE5 in a competitive manner (IC50=0.23 nM). T-0156 free base inhibits PDE6 (IC50=56 nM) and has low potencies against PDE1, PDE2, PDE3, and PDE4 (IC50>10 μM). T-0156 free base enhances the nitric oxide (NO)/cGMP pathway .
    T-0156 free base
  • HY-180803
    LH17

    		Phosphodiesterase (PDE) Inflammation/Immunology
    LH17, a Kaempferol (HY-14590) derivative, is a potent and selective PDE4 inhibitor (PDE4D2 IC50 = 73 nM, PDE4B2 IC50 = 190 nM). LH17 exhibits remarkable selectivity (>136-fold) against other PDE isoforms (PDE1B/2A/3A/5A/8A/9A/10A) (IC50 > 10000 nM), with the exception of PDE7A1 (IC50 = 300 nM). LH17 distinctly interacts with PDE4 M-pocket. LH17 demonstrates remarkable anti-fibrotic efficacy in both in vitro and in vivo models. LH17 can be used for idiopathic pulmonary fibrosis (IPF) research .
    LH17
  • HY-14254R
    Olprinone Hydrochloride (Standard)

    LoprINone Hydrochloride (Standard)

    		 Phosphodiesterase (PDE) Reference Standards Cardiovascular Disease
    Olprinone (Hydrochloride) (Standard) is the analytical standard of Olprinone (Hydrochloride). This product is intended for research and analytical applications. Olprinone (Loprinone) Hydrochloride is a potent phosphodiesterase (PDE) 3 inhibitor, with IC50s of 150, 100, 0.35 and 14 μM for PDE1, PDE2, PDE3 and PDE4, respectively. Olprinone Hydrochloride is used for the research of heart failure due to its positive inotropic and vasodilative effects. Anti-inflammatory activity .
    Olprinone Hydrochloride (Standard)

Consulta en línea

Your information is safe with us. * Required Fields.

Saludo

  

Country or Region *

Nombre del solicitante *

 

Nombre de la Organizaciòn *

Department *

     

Direcciòn del E-mail *

 

Nombre del producto *

Cat. No.

  

Requested quantity *

Número de teléfono *

     

Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: